Form 4: Carisma Therapeutics CEO Steven Kelly Acquires 500,000 Stock Options

Steven Kelly, President and CEO of Carisma Therapeutics Inc., reports the acquisition of 500,000 stock options on January 28, 2025.

Summary

• This Form 4 filing reports a change in beneficial ownership for Steven Kelly, the President and CEO of Carisma Therapeutics Inc.
• On January 28, 2025, Kelly acquired 500,000 stock options with an exercise price of $0.50.
• The options vest over four years in equal monthly installments, contingent upon continued service to Carisma Therapeutics Inc.
• The options expire on January 28, 2035.
• Following the transaction, Kelly directly owns 500,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing. The acquisition of stock options by the CEO could be interpreted as a slightly positive signal, but it's not definitively bullish.

Positives

• The acquisition of stock options by the CEO could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the CEO's increased stake in the company through stock options.

Stakeholder Impact

• The acquisition of stock options by the CEO may have a slightly positive impact on shareholder sentiment.

Key Dates